Rezultati pretraživanja
  1. 3. velj

    -altered : clinical features and therapeutic outcomes to standard systemic therapies, PARP, and PD1 inhibitors presented by Emmanuel Antonarakis, MB BCh coverage by on UroToday.

  2. 3. velj

    EV-103: Enfortumab Vedotin plus Pembrolizumab : Andrew Krivoshik, MD of explains insights on EV-103 enfortumab vedotin plus pembrolizumab that was presented at ESMO.

  3. 2. velj

    Efficacy & biomarker analysis of pts with adv. RCC with sarcomatoid histology: subgroup analysis from renal 101 presentations by . coverage by on UroToday > .

  4. 1. velj

    Patient-reported outcomes from in patients with mCSPC discussion by . Written coverage by on UroToday >

  5. 1. velj
  6. 1. velj

    study of Niraparib in patients with and biallelic DNA-repair gene defects. A pre-specified interim analysis discussion by Mattew Smith, MD, PhD. coverage by on UroToday.

  7. 31. sij

    . atezolizumab + bevacizumab Increased OS & PFS in Unresectable Hepatocellular Carcinoma (HCC) [Oct 21, 2019] IMbrave150 HT noted Video

    Prikaži ovu nit
  8. 31. sij

    Incyte Announces Positive Updated Results from FIGHT-202 Phase 2 Trial of Pemigatinib FGFR inhibitor in Previously Treated, Advanced Cholangiocarcinoma [Sep 27, 2019] Abstract HT

    Prikaži ovu nit
  9. 31. sij

    MT [Sep 27, 2019] Number of actionable targets in this target-rich disease are increasing with encouraging results.

    Prikaži ovu nit
  10. 31. sij

    MT [Sep 27, 2019] Pemigatinib in intrahepatic cholangio ca with FGFR fusions/ rearrangements.

    Prikaži ovu nit
  11. 31. sij

    Setting up genomic tumor boards – What can be done and what needs to be done discussion by Scott Tomlins, MD, PhD . Written coverage by on UroToday.

  12. 31. sij

    Invited discussant thoughts on , -altered , preliminary results from , and in tumor tissue from men with mCRPC screened for Written coverage by .

  13. 31. sij

    Diagnosis, management, and burden of renal cell carcinomas: results from a global patient survey in 43 countries discussion by . Written coverage by on UroToday >

  14. 30. sij

    VIDEO: Prof. Siefker-Radtke on the EV-103 trial in bladder cancer w/ Arlene Siefker-Radtke of :

  15. 30. sij

    Central, prospective detection of homologous recombination repair gene mutations (HRRm) in tumor tissue from >4000 men with screened for , discussion by at . Written coverage by >

  16. 30. sij

    VIDEO: Predicting resistance to targeted therapies in melanoma w/ Christian Blank from :

  17. 30. sij

    ENTRATA Study: How does it affect clinicians today? : Chung-Han Lee, MD of answers how it affects clinicians and what is to come in kidney cancer. _______ Data shared today in oral presentation at ESMO Congress 2019…

  18. 29. sij

    An adaptive biomarker-directed platform study with Durvalumab in combination w/ targeted therapies in metastatic urothelial cancer presentation by . coverage by on UroToday.

  19. 29. sij

    Invited Discussant Christian Kollmannsberger, MD discussion of germ cell tumor studies and RCC disease management methods. Written coverage by on UroToday.

  20. 29. sij

    VIDEO: REACH safety data: avelumab plus RT-cetuximab in LA SCCHN w/ Jean Bourhis from :

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.